Our scientists are advancing novel programs that are intended to transform pulmonary arterial hypertension into a chronic, manageable condition, ultimately with the goal of halting it.
Working in partnership with the Pulmonary Hypertension Therapeutic Area team, the Cardiovascular & Metabolism Therapeutic Area is responsible for the discovery research effort in pulmonary arterial hypertension (PAH).
PAH affects a relatively young population, limiting survival and impairing daily life, even when treatment is optimal. While the immediate goal is to prolong survival, we also aim to improve the quality of life for those living with this disease.
With research and discovery programs shared across our therapeutic areas, we are committing significant discovery resources to uncover the most promising mechanisms that can modify the course of PAH. The goal for us is to reverse the underlying pathologies in PAH and resolve the disease itself.
To do so, we are tapping into our deep in-vitro and in-vivo expertise, as well as connection with patient and research communities to fully understand the challenges and risks associated with PAH.